Research Grade Anti-Human IL6 (WBP 216) (HY328166)

Fiche technique Partager le produit Copier les informations

Prix(USD) : $

Spécification :

100ug
1mg

Nombre :

Contactez-nous

Aperçu
Images
Reférences
Fiche technique

Aperçu

Numéro de catalogue	HY328166
Description	Anti-Human IL6 (WBP 216) (HY328166) is a research-grade recombinant antibody targeting Hybridoma growth factor. Produced in mammalian cells with native-like glycosylation. Highlights ●Research Grade — For PK/PD studies, assay development, and ADA research. ●Native Glycosylation — Mammalian expression ensures native-like patterns.
Reactivité des espèces	Human
Applications	ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Espèce hôte	Human
Isotype	IgG
ID de clone	WBP 216
Système d'expression	Mammalian Cells
Clonalité	Monoclonal
Cible	Hybridoma growth factor, BSF-2, IFN-beta-2, CDF, IL6, Interleukin-6, IL-6, B-cell stimulatory factor 2, Interferon beta-2, IFNB2, CTL differentiation factor
Niveau d'endotoxines	Please contact the lab for this information.
Pureté	>95% purity as determined by SDS-PAGE.
Purification	Protein A/G purified from cell culture supernatant.
Numéro d'accès	P05231
Forme	Liquid
Tampon de stockage	0.01M PBS, pH 7.4. Reférez-vous aux informations spécifiques sur le tampon dans la copie papier du datasheet ou dans le COA spécifique au lot.
Stabilité et stockage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C.
Noms alternatifs	WBP-216, WBP216, WBP216
Contexte	Interleukin-6 (IL6) is a ~23 kDa protein. Cytokine with a wide variety of biological functions in immunity, tissue regeneration, and metabolism. Binds to IL6R, then the complex associates to the signaling subunit IL6ST/gp130 to trigger the intracellular IL6-signaling pathway (Probable). The interaction with the membrane-bound IL6R and IL6ST stimulates 'classic signaling', whereas the binding of IL6 and soluble IL6R to IL6ST stimulates 'trans-signaling'. Alternatively, 'cluster signaling' occurs when membrane-bound IL6:IL6R complexes on transmitter cells activate IL6ST receptors on neighboring receiver cells (Probable). IL6 is the therapeutic target of tocilizumab (Actemra).
Note	For research use only. Not suitable for clinical or therapeutic use.